Cytokines and NO in American tegumentary leishmaniasis patients: Profiles in active disease, after therapy and in self-healed individuals

Microbial Pathogenesis

Volumn 57, Issue , 2013, Pages 27-32

  De Assis Souza, Marina ^a   Brelaz de Castro, Maria C A ^a   De Oliveira, Andresa Pereira ^a   De Almeida, Amanda Ferreira ^a   De Almeida, Thays Miranda ^a   Reis, Luiza C ^b   Medeiros, Ângela Cristina Rapela ^c   De Brito, Maria Edileuza Felinto ^a   Pereira, Valéria Rêgo Alves ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cellular immunity; Cytokines; Leishmania braziliensis; Leishmaniasis; Nitric oxide

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; MEGLUMINE ANTIMONATE; NITRIC OXIDE; PARASITE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; AMERICAN TEGUMENTARY LEISHMANIASIS; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; HEALING; HUMAN; LEISHMANIA BRAZILIENSIS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SKIN LEISHMANIASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NITRIC OXIDE; YOUNG ADULT;

EID: 84874797767     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2013.02.004     Document Type: Article

References (40)

1. Gontijo B., Carvalho M.L.R. Leishmaniose Tegumentar Americana. Rev Soc Bras Med Trop 2003, 36(1):71-80.
2. Basano S.A., Camargo L.M.A. Leishmaniose Tegumentar Americana: histórico, epidemiologia e perspectivas de controle. Rev Bras Epidemiol 2004, 7:328-337.
3. Castellucci L., Jamieson S.E., Almeida L., Oliveira J., Guimarães L.H., Lessa M., et al. Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil. Infect Genet Evol 2012, 12:1102-1110.
4. Bacellar O., Lessa H., Schriefer A., Machado P., Ribeiro de Jesus A., Dutra W.O., et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002, 70(12):6734-6740.
5. Reis L.C., Brito M.E.F., Souza M.A., Pereira V.R.A. Mecanismos imunológicos na resposta celular e humoral na leishmaniose tegumentar americana. Rev Patol Trop 2006, 35(2):103-115.
6. Coutinho S.G., Oliveira M.P., Da Cruz A.M., De Luca P.M., Mendonça S.G., Bertho A.L., et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 1996, 84:144-155.
7. Von Stebut E. Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 2007, 16:340-346.
8. Bacellar O., Faria D., Nascimento M., Cardoso T.M., Gollob K.J., Dutra W.O., et al. Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis 2009, 200:75-78.
9. H17 cells. Nature 2008, 453(19):1051-1057.
10. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
11. Pitta M.R.G., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009, 119(8):2379-2387.
12. Antonelli L.R.V., Dutra W.O., Almeida R.P., Bacellar O., Gollob K.J. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 2004, 136:341-348.
13. Toledo V.P.C.P., Mayrink W., Gollob K.J., Oliveira M.A., Costa C.A., Genaro O., et al. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001, 96:89-98.
14. Da Cruz A.M., Bittar R., Mattos M., Oliveira-Neto M.P., Nogueira R., Pinho-Ribeiro V., et al. T-cell mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol 2002, 9(2):251-256.
15. Souza M.A., Castro M.C.A.B., Oliveira A.P., Almeida A.F., Reis L.C., Silva C.J., et al. American tegumentary leishmaniasis: cytokines and nitric oxide in active disease and after clinical cure, with or without chemotherapy. Scand J Immunol 2012, 76:175-180.
16. Brito M.E., Mendonça M.G., Gomes Y.M., Jardim M.L., Abath F.G. Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2001, 95:203-206.
17. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
18. Brandão-Filho S.P., Brito M.E., Carvalho F.G., Ishikawa E.A., Cupolillo E., Floeter-Winter L., et al. Wild and synanthropic hosts of Leishmania (Viannia) braziliensis in the endemic cutaneous leishmaniasis locality of Amaraji, Pernambuco State, Brazil. Trans R Soc Trop Med Hyg 2003, 97(3):291-296.
19. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S., et al. Cutaneous Leishmaniasis. Lancet Infect Dis 2007, 7:581-596.
20. Carvalho E.M., Correia Filho D., Bacellar O., Almeida R.P., Lessa H., Rocha H., et al. Characterization of the immune response in subjects with self healing cutaneous leishmaniasis. Am J Trop Med Hyg 1995, 53(3):273-277.
21. Gomes-Silva A., Bittar R.C., Dos Santos Nogueira R., Amato V.S., da Silva Mattos M., Oliveira-Neto M.P., et al. Can interferon-γ and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?. Clin Exp Immunol 2007, 149:440-444.
22. Telino E., De Luca P.M., Matos D.C.S., Azeredo-Coutinho R.B., Meirelles M.N., Conceição-Silva F., et al. In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes. Clin Exp Immunol 2005, 143(2):338-344.
23. Berger B.J., Fairlamb A.H. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniasis. Parasitology 1992, 105:S71-S78.
24. Coutinho S.G., Da Cruz A.M., Bertho A.L., Santiago M.A., De Luca P. Immunologic patterns associated with cure in human American cutaneous leishmaniasis. Braz J Med Biol Res 1998, 31:139-142.
25. Kocyigit A., Gur S., Gurel M.S., Bulut V., Ulukanligil M. Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis. Infect Immun 2002, 70(12):6589-6591.
26. Muniz-Junqueira M.I., Paula-Coelho V.N. Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-α production, but only via TNF-α it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int Immunopharmacol 2008, 8:1633-1638.
27. Cabrera M., Shaw M.A., Sharples C., Williams H., Castes M., Convit J., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995, 182(5):1259-1264.
28. Gorak P.M., Engwerda C.R., Kaye P.M. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998, 28:687-695.
29. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354:1191-1199.
30. Kane M.M., Mosser D.M. Leishmania parasites and their plays to disrupt macrophage activation. Curr Opin Hematol 2000, 7:26-31.
31. Saha P., Mukhopadhyay D., Chatterjee M. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Int Immunopharmacol 2011, 11:1668-1679.
32. Gollob K.J., Antonelli L.R.V., Faria D.R., Keseen T.S.L., Dutra W.O. Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology. Int Immunopharmacol 2008, 8:1338-1343.
33. Mendonça M.G., Brito M.E.F., Rodrigues E.H.G., Bandeira V., Jardim M.L., Abath F.G.C. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?. J Infect Dis 2004, 189:1018-1023.
34. Orkwor I., Uzonna J. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 2008, 41(2):123-136.
35. Amato V.S., Andrade H.F., Duarte M.I.S. Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment. Acta Trop 2003, 85:39-49.
36. Matsuzaki G., Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007, 51:1139-1147.
37. Niedbala W., Alves-Filho J.C., Fukada S.Y., Vieira S.M., Mitani A., Sonego F., et al. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. Proc Natl Acad Sci U S A 2011, 108(22):9220-9225.
38. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T Helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
39. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010, 207(6):1293-1304.
40. Reis L.C., Brito M.E., Souza M.A., Medeiros A.C., Silva C.J., Luna C.F., et al. Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment. J Clin Lab Anal 2009, 23(1):63-69.